Equillium (NASDAQ:EQ) Stock Price Up 1.1%

Equillium, Inc. (NASDAQ:EQ) traded up 1.1% on Thursday . The stock traded as high as $1.85 and last traded at $1.81. 130,386 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 315,095 shares. The stock had previously closed at $1.79.

Analyst Ratings Changes

Separately, HC Wainwright increased their price objective on Equillium from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, April 2nd.

Equillium Stock Up 1.1 %

The business’s 50-day moving average price is $2.30 and its 200 day moving average price is $1.28. The company has a market capitalization of $63.82 million, a P/E ratio of -4.64 and a beta of 1.62.

Equillium (NASDAQ:EQ) last posted its earnings results on Monday, March 25th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.10. The business had revenue of $9.21 million for the quarter, compared to analysts’ expectations of $8.85 million. Equillium had a negative net margin of 36.96% and a negative return on equity of 51.82%. Analysts anticipate that Equillium, Inc. will post -0.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Equillium

A hedge fund recently bought a new stake in Equillium stock. Decheng Capital LLC purchased a new position in Equillium, Inc. (NASDAQ:EQ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,447,308 shares of the company’s stock, valued at approximately $3,215,000. Equillium comprises about 0.9% of Decheng Capital LLC’s holdings, making the stock its 18th largest holding. Decheng Capital LLC owned about 12.66% of Equillium at the end of the most recent quarter. 27.05% of the stock is owned by institutional investors.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.